For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
✓500+ PubMed Citations✓No Affiliate Links✓Private & Secure
The Lab

BPC-157 vs TB-500: Comparing Healing Peptide Research

PeptaBase Research Review | 2026-01-14

Overview

BPC-157 and TB-500 are the most-researched healing peptides. They're often used together, but they're completely different compounds with different mechanisms. Here's how they differ.

BPC-157: Blood Vessels & Cytoprotection

BPC-157 comes from a gastric protein. Its job is protecting cells during injury.

Mechanisms:

  • Blood vessel growth - BPC-157 ramps up VEGF, creating new capillaries in damaged tissue
  • Nitric oxide - it boosts NO signaling, improving blood flow and reducing inflammation
  • Gut healing - strongest research is in GI ulcer models; it protects stomach lining
  • Tendon/ligament - improves collagen organization and fibroblast work

Half-life: about 4 hours, though data is limited. Local injection might last longer at the injury site.

TB-500: Cell Movement & Cytoskeleton

TB-500 is a synthetic version of Thymosin Beta-4. The active part is the Ac-SDKP sequence.

Mechanisms:

  • Actin binding - binds actin and rearranges the cell skeleton, letting cells move and repair
  • Cell migration - draws skin cells, endothelial cells, and muscle cells to injury sites
  • Anti-inflammatory - some evidence of reduced inflammatory markers during healing
  • Muscle and heart repair - studied in muscle and cardiac damage, not just tendon

Half-life: longer than BPC-157, but exact data is sparse. It distributes throughout the body, making it better for systemic injuries than localized ones.

Key Differences in Research Context

| Feature | BPC-157 | TB-500 | |---|---|---| | Origin | Gastric protein fragment | Thymosin Beta-4 analog | | Primary mechanism | Angiogenesis / cytoprotection | Actin regulation / cell migration | | GI research | Extensive | Minimal | | Half-life estimate | ~4 hours | Longer (less characterized) | | Administration | Systemic or localized | Primarily systemic |

Combined Use in Research Protocols

Since the two peptides work differently-BPC-157 makes blood vessels and protects cells, TB-500 moves cells and fixes structure-many protocols stack them. The idea: TB-500 recruits repair cells and calms inflammation early on, while BPC-157 builds blood vessels and strengthens tissue later.

This is empirical-there are no rigorous combination studies comparing them head-to-head.

Evidence Level

Both are preclinical. Almost all data is from rodent studies. Human evidence is anecdotal and small-scale. Treat them as experimental.

--- For research use only. Not medical advice.

Key References